Please assess the completion status of the following clinical trial:

Trial Title: Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women must be at least 18 years of age at the time of screening~* Chronic plaque-type psoriasis diagnosed for at least 6 months before randomization Patients with moderate to severe plaque psoriasis who are candidates for systemic therapy as defined at randomization by:~* PASI score of \>10~* Affected body surface area (BSA) \> 10%~* DLQI \>10~* Inadequate response, intolerance or contraindication to topical psoriasis treatment as documented in the patient's medical history or reported by the patient or determined by the investigator at screening.~Exclusion Criteria (abbreviated):~* Previous systemic treatment of plaque psoriasis or known contraindication for systemic therapy at baseline~* Ongoing use of other prohibited psoriasis and non-psoriasis treatment.~* Clinically important active infections or infestations, chronic, recurrent or latent infections or infestations~* Patients with severe liver diseases~* Patients with severe gastrointestinal diseases including but not limited to ventricular and duodenal ulcers~* Patients with severe kidney diseases or serum creatinine above 1 x ULN~* Patients with known hematological disease or lab abnormalities~* Pregnancy, breast feeding, or unwillingness/inability to use appropriate measures of contraception (if necessary)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab (Type: EXPERIMENTAL): Patients in treatment arm A will receive a dose of 300 mg secukinumab administered as 2 subcutaneous injections of 150 mg in a SensoReady pen (i.e. 2 x 150 mg) at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20.
- Fumaric acid (initial and maintenance therapy) (Type: ACTIVE_COMPARATOR): Participants were daily self-administered with fumaric acid derivatives initial and maintenance therapy in dosetitrated scheme as per protocol. Dose was up-titrated weekly (1 tablet/day) until objective was achieved or until tapering was required or until the maximum dose of 2 tablets each at morning, noon and evening was reached, whichever occurred earlier.

Based on this trial design, predict the completion outcome and termination type (if applicable).